Form D · Pharmaceuticals
Labrys Biologics, Inc.
San Francisco, CA · CIK 0001564179
Offering snapshot reported Dec 28, 2012 · SEC filing
- Reported sold
- $14.6M Offering amount: $31M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 21, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 28, 2012 | Initial | $14,588,234 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-189143
Series A Preferred Stock
Source: Form D, filed Dec 28, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Adelman | Executive |
| Corey Goodman | Director, Executive |
| Wende Hutton | Director |
| Steve P. James | Director, Executive, Promoter |
| Nina S. Kjellson | Director |
| Michael F. Powell | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1700 Owens Street Suite 595
San Francisco, CA, 94158
San Francisco, CA, 94158